Beta Bionics, Inc.
BBNX
$14.82
-$0.20-1.33%
| Weiss Ratings | BBNX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Unrated | |||
| Risk Index | Unrated | |||
| Risk Grade | U | |||
| Reward Grade | U | |||
| Rating Factors | BBNX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | Unrated | |||
| Growth Index | Unrated | |||
| Efficiency Index | Unrated | |||
| Solvency Index | Unrated | |||
| Total Return Index | Unrated | |||
| Volatility Index | Unrated | |||
| Beta / Standard Deviation | BBNX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | -- | |||
| Price History | BBNX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -29.36% | |||
| 30-Day Total Return | -- | |||
| 60-Day Total Return | -- | |||
| 90-Day Total Return | -- | |||
| Year to Date Total Return | -37.28% | |||
| 1-Year Total Return | -- | |||
| 2-Year Total Return | -- | |||
| 3-Year Total Return | -- | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -38.69% | |||
| 52-Week Low % Change | 10.12% | |||
| Price | BBNX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $24.50 | |||
| 52-Week Low Price | $13.64 | |||
| 52-Week Low Price (Date) | Mar 10, 2025 | |||
| 52-Week High Price (Date) | Jan 30, 2025 | |||
| Valuation | BBNX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 643.75M | |||
| Enterprise Value | 851.86M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -1.55 | |||
| Earnings Per Share Growth | -9.36% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 5.63 | |||
| Price/Book (Q) | -0.44 | |||
| Enterprise Value/Revenue (TTM) | 50.99 | |||
| Price | $14.82 | |||
| Enterprise Value/EBITDA (TTM) | -79.83 | |||
| Enterprise Value/EBIT | -77.60 | |||
| Market Cap Category | Small Cap | |||
| Dividends and Shares | BBNX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 6.26M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | BBNX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 949 427 7785 | |||
| Address | 11 Hughes Irvine, CA 92618 | |||
| Website | www.betabionics.com | |||
| Country | United States | |||
| Year Founded | 2015 | |||
| Profitability | BBNX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -- | |||
| Profit Margin | -- | |||
| Management Effectiveness | BBNX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -- | |||
| Return on Equity | -- | |||
| Income Statement | BBNX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | -- | |||
| Revenue Per Share | $2.67 | |||
| Gross Profit (TTM) | -- | |||
| EBITDA (TTM) | -- | |||
| EBIT (TTM) | -- | |||
| Net Income (TTM) | -- | |||
| Net Income Avl. to Common (TTM) | -- | |||
| Total Revenue Growth (Q YOY) | 440.09% | |||
| Earnings Growth (Q YOY) | -12.17% | |||
| EPS Diluted (TTM) | -- | |||
| EPS Diluted Growth (Q YOY) | 9.35% | |||
| Balance Sheet | BBNX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 60.90M | |||
| Cash Per Share (Q) | $9.72 | |||
| Total Current Assets (Q) | 82.56M | |||
| Total Preferred Equity (Q) | 261.71 | |||
| Total Equity (Q) | 32.87M | |||
| Current Ratio (Q) | 4.617 | |||
| Book Value Per Share (Q) | -$34.35 | |||
| Total Assets (Q) | 96.94M | |||
| Total Current Liabilities (Q) | 17.88M | |||
| Total Debt (Q) | 7.30M | |||
| Total Liabilities (Q) | 64.07M | |||
| Total Common Equity (Q) | -228.85M | |||
| Cash Flow | BBNX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -- | |||
| Cash from Financing (TTM) | -- | |||
| Net Change in Cash (TTM) | -- | |||
| Levered Free Cash Flow (TTM) | -- | |||
| Cash from Operations (TTM) | -- | |||
